AnaptysBio Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for AnaptysBio, Inc. (ANAB) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-145.23-163.62-128.72-57.80-19.93-97.34-61.66
Depreciation & Amortization2.402.382.342.091.62-2.120.32
Stock Based Compensation34.0533.2127.3615.3511.500.000.00
Change in Working Capital-66.33-0.328.34-7.49-7.8316.853.46
Change in Accounts Receivable-33.91-5.43-0.54-0.880.000.000.00
Change in Accounts Payable-33.8410.949.70-4.74-7.690.000.00
Change in Other Working Capital1.43-5.8321.11-1.87-0.140.000.00
Other Operating Activities39.7718.0844.451.4510.8013.090.65
Net Cash from Operating Activities-135.34-120.80-73.59-45.92-14.16-69.52-48.51
Investing Activities
Capital Expenditures-0.36-0.810.36-1.37-0.570.81-1.06
Purchases of Investments-380.38145.56-802.5040.1995.040.000.00
Sales/Maturities of Investments476.13449.48-394.4940.1995.04132.24-141.39
Net Cash from Investing Activities95.40144.75-394.8538.8494.48131.43-142.45
Financing Activities
Debt Repayment34.770.000.000.00-1.38-7.50-6.88
Common Stock Issued100.842.4711.832.550.500.00227.48
Common Stock Repurchased-0.46-50.000.000.000.000.000.00
Other Financing Activities-8.10-11.7732.19249.750.000.00-0.18
Net Cash from Financing Activities127.05-59.3044.02252.30-0.88-4.49223.36
Summary
Net Change in Cash87.12-35.34-424.42245.2179.4457.4232.41
Cash at Beginning of Period35.9771.31495.73250.52171.08113.6681.25
Cash at End of Period123.0835.9771.31495.73250.52171.08113.66
Free Cash Flow-135.70-121.61-73.95-47.29-14.73-70.32-49.57
Supplemental Disclosures
Interest Paid0.000.000.000.000.000.421.04